Hi [[ session.user.profile.firstName ]]

Forensic Science

  • Predictive assays: Analytic validation, clinical validation and clinical utility Predictive assays: Analytic validation, clinical validation and clinical utility Krista Acosta, Nicole Schechter, PSM, PMP, Al Yates, PhD Recorded: Aug 25 2016 55 mins
    Predictive assays are a key element of personalized healthcare because these assays aid physicians in selecting individuals who are most likely or least likely to benefit from specific therapies. In addition to analytical validation, predictive assays require clinical validation to establish their clinical utility. Krista Acosta, Manager, CDx Pharma Services Assay Development, Nicole Schechter, PSM, PMP, CDx Director, Project Leader and Alton Yates PhD, Senior Manager, Clinical Sciences Management, will address the development and performance differences between predictive assays developed under in vitro diagnostic regulations and laboratory developed tests.
  • Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes Malcolm Qualie, NHS England, Nina Pinwill, NICE, Katie Pascoe, ABPI, Angela McFarlane, IMS Health Toby Gosden, IMS Health Recorded: Aug 2 2016 69 mins
    Join us for a one-hour live debate on Cancer Treatment Access: Right Strategy, Right Approach, Right Outcomes.

    To ensure funding and patient access to innovative cancer therapies, industry now have to navigate a new English cancer-treatment funding ecosystem, engaging with NICE and NHS England to realise a yes, no or conditional arrangement.

    How can oncology treatments achieve a positive NICE appraisal in the new world and what will the mechanics of RWE be in the event of conditional funding via the reformed cancer drugs fund?
  • What do the upcoming changes to England's pharmacy funding mean? What do the upcoming changes to England's pharmacy funding mean? John Smith, PAGB, Rob Darracott, Pharmacy Voice, Sandra Gidley, English Pharmacy Board Recorded: Jul 21 2016 67 mins
    New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades. The impact will go beyond community pharmacies as other stakeholders also feel the pressure.

    UK pharmacies already support more inhabitants per pharmacy than other major European markets; how will this funding change impact how patients are cared for in the community? How will pharmacy suppliers, such as consumer health companies, operate in the increasingly cost constrained and competitive environment?

    Working with our partner, IMS Health, we present an interactive webinar to share market insight on the potential impact and a live discussion with critical stakeholders of this change. Hear directly from key stakeholders about their thoughts of how the changes will play out, and what this means for you in your sector.
  • Multichannel Maturometer 2016 results: Key global trends Multichannel Maturometer 2016 results: Key global trends Ruud Kooi ( VP Business Development, Across Health), Dirk Szynka (MD, Across Health Germany) Recorded: Jul 14 2016 39 mins
    Key topics:

    - Digital maturity of pharma
    - Hot trends in multichannel marketing
    - Evolution of digital budgets
    - Key barriers
  • BREXIT: What's next for pharma? BREXIT: What's next for pharma? Stephen Dorrell, Chair NHS Confederation, Leslie Galloway, EMIG, Prof. Mike Bewick, prev NHS England, Dr Rick Greville, ABPI Recorded: Jul 14 2016 71 mins
    The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world.

    Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the crown of UKPLC - being heard in Westminster - and Brussels?

    In order to better understand the potential impact of Brexit on both pharma and healthcare in the UK, we are working with specialist IMS Health to bring a unique debate in which a hand-picked panel of experts will discuss and analyse:

    The impact of Brexit on UK Healthcare
    The ramification of Brexit for pharma in the UK
    What does the Brexit scenario mean for global pharma?
  • Establishing a Solid Foundation for Digital Transformation Establishing a Solid Foundation for Digital Transformation Alexandre Gultzgoff, Deputy Director, IT, Sanofi Pasteur MSD Antoine Blanc, Commercial Excellence Director, Sanofi Pasteur MS Recorded: Jul 12 2016 63 mins
    Sanofi Pasteur MSD is transforming its commercial organisation and remodeling its approach to customer engagement. Hear from Sanofi Pasteur MSD’s Alexandre Gultzgoff, Deputy Director, IT, and Antoine Blanc, Commercial Excellence Director, as they share first hand insights on how they are transforming their European commercial operations and improving customer engagement. Learn from their best practice as they share Sanofi Pasteur MSD’s:
    · Vision and strategy for digital transformation
    · Digital channels (CLM, email) to improve customer engagement
    · Deployment of a digital supply chain in ensuring fresh content to channels and content reuse
  • What's next for patient-centricity? How do we know when we are patient-centric? What's next for patient-centricity? How do we know when we are patient-centric? Jo Fearnhead-Wymbs, Ashfield Healthcare, Anita Osborn, Ashfield Clinical, Andrew Schorr, Patient Power, Paul Robinson, MS Recorded: Jul 5 2016 63 mins
    This webinar will delve into the challenges that pharma face when looking at their patient-centricity strategy, and the opportunities that exist with this approach. We will explore the key motivators for this approach, and steps to overcome the internal and external barriers, and most importantly – how do pharma companies know when they have become truly patient-centric? How should they measure the impact of their strategy through the lifecycle of a drug and their business as a whole?
  • Transforming Medical Affairs with fact-based solutions and improved compliance Transforming Medical Affairs with fact-based solutions and improved compliance Blake Morrison; Harleen Parmar; Seth Whitelaw; Paul Tunnah Recorded: Jun 28 2016 67 mins
    In today’s competitive, highly regulated environment, product success is dependent upon data and fact-based decision making. More and more, Medical Affairs teams play a pivotal role in education pre- and post-launch, yet the explosion of big data in healthcare is changing how we make value-based decisions that are critical to success.

    This webinar will explore the challenges Medical Affairs teams have finding a repeatable, objective and compliant solution to identify and manage their strategic programs.

    With a wealth of information available, it can be difficult to sort through data and understand what is important to incorporate into research and strategy. In this session you’ll hear needs and use cases for having a robust data strategy when it comes to Medical Affairs success. The panelists will share best practices for making fact-based decisions that meet compliance restrictions, using powerful market insights gained from multiple data sources, to optimize strategic planning and ultimately drive product success.
  • Social medical: The social media buzz around ASCO 2016 Social medical: The social media buzz around ASCO 2016 Paul Tunnah, Dr Mike Thompson, Dr Richard Simcock, Silja Chouquet, Andrew Schorr Recorded: Jun 27 2016 64 mins
    The ASCO Annual Meeting, the largest global oncology meeting and increasingly the centre of a kaleidoscope of social media coverage each year.

    As a snapshot, 2014 saw 40,000 tweets and 140m+ impressions over the conference days, 2015 grew to 60,000 tweets and 250m+ impressions and the 2016 buzz is already louder and more plentiful than last year.

    This webinar will examine the conversation around ASCO 2016, its relationship with ASCO, value to and involvement from stakeholder groups and how it will potentially continue to evolve into 2017.
  • Skin Cancer and Immunohistochemistry Skin Cancer and Immunohistochemistry Jeff Gordon, Director OEM Sales - Cell Marque Corporation, Rocklin CA Recorded: Jun 22 2016 63 mins
    Skin cancer is by far the most prevalent cancer. Each year, approximately 3.4 million people in the US alone are diagnosed with some form of skin cancer. Skin cancer can be highly treatable if it is detected and classified early, and this detection and classification is often aided by immunohistochemistry. This presentation covers many of the basic science, facts, and statistics of skin cancer, as well as the utility of immunohistochemical testing with markers such as S-100, SOX-10, Ber-Ep4, and HHV-8 in the accurate diagnosis and survival rates of skin cancer. Continuing education credits for attending this webinar will be offered through the National Society of Histotechnology
  • Growing Cell Line Potential: From Lab To Licence S2 Growing Cell Line Potential: From Lab To Licence S2 Dr. Lily Chan, Cambridge Enterprise Recorded: Jun 9 2016 26 mins
    A scientific overview of the portfolio of cell lines University of Cambridge has deposited at ECACC with a focus on the KARPAS 299 and KARPAS 422 cell lines; the HeLa Mitotrap cell lines; and CHO cell lines. We will also provide an overview of the process of partnering with ECACC and Sigma-Aldrich for the storage and distribution of cell lines for research purposes. Topics include: The scientific applications of the cell lines; The types of companies and institutions we license to; Advantages of partnering with culture experts and specialised distributors; Our experience of working with ECACC and Sigma-Aldrich.
  • Growing Cell Line Potential: From Lab To Licence S1 Growing Cell Line Potential: From Lab To Licence S1 Dr. Lily Chan, Cambridge Enterprise Recorded: Jun 9 2016 24 mins
    A scientific overview of the portfolio of cell lines University of Cambridge has deposited at ECACC with a focus on the KARPAS 299 and KARPAS 422 cell lines; the HeLa Mitotrap cell lines; and CHO cell lines. We will also provide an overview of the process of partnering with ECACC and Sigma-Aldrich for the storage and distribution of cell lines for research purposes. Topics include: The scientific applications of the cell lines; The types of companies and institutions we license to; Advantages of partnering with culture experts and specialised distributors; Our experience of working with ECACC and Sigma-Aldrich.
  • Impact measurement; from counting numbers to actionable insights Impact measurement; from counting numbers to actionable insights Jan Keuppens (VP Integrated Execution, Across Health) and Christophe Brock (Senior Consultant, Across Health) Recorded: May 31 2016 52 mins
    The key topics that will be discussed during this interactive webinar include:

    •The AH impact measurement approach; Exposure, engagement, conversion and effectiveness
    •Defining KPIs relevant to your brand strategy & objectives
    •Best case – Worst case
    •Creating a dashboard
    •Q&A
  • Finally -- Evidence-Based Best Practices For Using UV Disinfection Equipment Finally -- Evidence-Based Best Practices For Using UV Disinfection Equipment Dr. William Jarvis MD, Dr. Thomas Kelley MD Recorded: May 25 2016 62 mins
    You wouldn’t operate a ventilator or administer an IV without knowing there are scientific studies that back up your procedures. You learned best practices supported by scientific research.

    We have the science and consensus to support UV disinfection best practices. Best practices that have resulted in infection rate reductions in real hospital environments.

    Your discussion will be led by esteemed experts Dr. William Jarvis and Dr. Thomas Kelley.

    William Jarvis, MD is a world leader in infection prevention. Among many other accomplishments he worked at the Centers for Disease Control and Prevention for 23 years, and has published over 450 peer reviewed papers. Recently it was said of Dr. Jarvis, “His decades of service and uncompromised commitment to [infection prevention] has lead to changes in how infection control is administered and has saved many lives.”

    Dr. Jarvis will discuss:
    -Most recent CDC and SHEA guidelines, and the metrics involved
    -A review of the science available on UV technologies in the market
    -What to look for when evaluating a UV technology

    Thomas Kelley, MD is Chief of Quality and Clinical Transformation at Orlando Health. He is a practicing primary care physician in Florida and has been a champion of quality improvement his entire career. He developed the first quality improvement council for the residency program when he was a faculty physician training residents at Atlanta Medical Center, and has continued to give his time and expertise to the causes of patient safety and quality care ever since. Colleagues say, “Dr. Kelley is a true champion for quality.”

    Dr. Kelley will discuss:
    -An integrated disinfection program with pulsed xenon enlightening best practices
    -Review of the results from a system-wide deployment of pulsed xenon light technology
    -How they achieved a $3.8M cost avoidance from HAI rate reduction in 12 months
  • What does 'the cloud' mean for pharma? What does 'the cloud' mean for pharma? Athula Herath (Novartis), Umang Patel (Babylon Health), Peter Emberson (UK Pharma IT Forum), Paul Tunnah (pharmaphorum) Recorded: May 4 2016 65 mins
    A unique Q&A session/open forum panel debate.

    It is likely that you interact with ‘the cloud’ on various devices, multiple times throughout the day. However, for pharma we have only just scratched the surface regarding what the cloud can offer in terms of security, connectivity and efficacy. ‘Business analytics’ and ‘cloud’ are often misunderstood.

    To answer this, pharmaphorum, in conjunction with industry stalwarts Equinix, present a unique Q&A event, offering the opportunity to ask any questions you may have around what the cloud can do, and how to remain compliant in utilising this technology.

    This debate is an open forum and the expert panel will offer insight about interaction between the cloud and pharma with a particular focus on:
    • Patient outcomes – The cloud and patients, what are the routes to improving outcomes?
    • Internet of things – As the ways to gather data and interact increase exponentially, how does the cloud support this? What are the opportunities and can we eliminate the risk?
    • Data and security – How to achieve compliance almost automatically.
    • Collaboration – Why and how the cloud enables true partnership working.
  • Disrupting and improving customer engagement with predictive insights Disrupting and improving customer engagement with predictive insights David Davidovic, Jerome Mead, Leilani Latimer, Paul Tunnah Recorded: Apr 27 2016 63 mins
    There are clear benefits for both Life Sciences companies and their customers in significantly improving the way they engage. Be it in terms of reputation, efficiency, profitability, or even relationship quality and longevity, engagement has and will always be the key to successful business practice.

    Recent exclusive research conducted in conjunction with Zephyr Health revealed that both frontline sales forces and sales management professionals want to improve engagement strategies with new technology utilizing predictive insights. However, despite having new tools available to them, sales teams remain heavily reliant on the same techniques that were being used decades ago.

    So what is the answer – how do life sciences companies disrupt this pattern and make significant strides to improve engagement?

    Working with Zephyr Health, we present an expert webinar that will answer this very question, bringing together industry experts to discuss why the disruption is critical, how it can be achieved, and the core role that predictive insights play in this process.

    As with all of our webcasts, this is an interactive debate designed to enable you to get the answers you need.

    Topics covered include:

    •Customer engagement challenges and trends: the need for disruptive customer engagement – what the survey revealed
    •The challenges facing Life Sciences customer engagement
    •Why technology is only partially solving the problem
    •The evolution of CRM: from historic analytics to current analytics to future analytics – knowing what your customer wants before they do
    •Overcoming internal blockers to change within Life Sciences – the roadmap for success
  • e-Medical excellence at launch e-Medical excellence at launch Fonny Schenck (CEO, Across Health) and Ben Harbour (MD, Across Health UK) Recorded: Apr 26 2016 58 mins
    This webinar will provide you with an overview how digital can be integrated into medical plans and what it takes to deliver multichannel medical excellence at launch.

    Key topics include:
    •Overview of typical launch categories and their key communication drivers and multichannel opportunities
    •The 4 main pre-launch stakeholders and how to integrate digital initiatives in a balanced medical mix whilst respecting legal and regulatory guidelines
    oeKOLs: Gathering insight and engagement planning
    oeHCPs: Channel selection to ensure immersive learning and education
    oePatients: Gathering treatment insight and prepare education & value-focused “beyond the-pill” strategies for launch
    oePayers: Establish value
    •Assess the clinical impact of e-medical programmes and how to create KPIs and dashboards to assess the success of your cross-channel activities
    •Prepare your organization for emedical excellence through multichannel skills development and enablement for MSLs and internal staff
  • The Creative Debate: Why creativity is key to true patient centricity in pharma The Creative Debate: Why creativity is key to true patient centricity in pharma Kai Gait, Maneesh Juneja, Lions Health jury member, Paul Tunnah Recorded: Apr 26 2016 66 mins
    Meeting the needs of both patients, and healthcare professionals, in today's fast changing communications landscape can be challenging, particularly against the backdrop of compliance. Putting creativity at the heart of the process can be the most effective way of tackling these challenges.

    Although the return on investment of creativity is not always easy to measure, the value it can bring to pharma and healthcare is increasingly evident.

    This webinar brings together a wealth of expertise to deliver case-study based evidence, interactive debate and practical advice on deriving competitive advantage from the creative process and ensuring patients are truly at the heart of your business.
  • Optimize Your Germ-Zapping Robot: Best practices & review of published studies Optimize Your Germ-Zapping Robot: Best practices & review of published studies Founder Dr. Mark Stibich, PhD Recorded: Apr 21 2016 60 mins
    PASSWORD: LightStrike -- Join this webinar to become an instant expert in xenon light room disinfection. Hear the latest evidence-based best practices for optimizing the use of Xenex Germ-Zapping Robots to tackle C. diff, MRSA and other difficult pathogens that linger in hospitals and post-acute care units.

    Hospitals across the country continue to publish infection rate reductions achieved using pulsed xenon light disinfection technology. Dr. Mark Stibich, Xenex Founder and Chief Scientific Officer, will discuss the published outcome studies to date and share best practices to help you reduce the risk of infection in your facility.
  • Optimize Your Germ-Zapping Robot: Best practices & review of published studies Optimize Your Germ-Zapping Robot: Best practices & review of published studies Founder Dr. Mark Stibich, PhD Recorded: Apr 20 2016 63 mins
    PASSWORD: LightStrike -- Join this webinar to become an instant expert in xenon light room disinfection. Hear the latest evidence-based best practices for optimizing the use of Xenex Germ-Zapping Robots to tackle C. diff, MRSA and other difficult pathogens that linger in hospitals and post-acute care units.

    Hospitals across the country continue to publish infection rate reductions achieved using pulsed xenon light disinfection technology. Dr. Mark Stibich, Xenex Founder and Chief Scientific Officer, will discuss the published outcome studies to date and share best practices to help you reduce the risk of infection in your facility.
  • LEAN High-Volume Hematology Solutions LEAN High-Volume Hematology Solutions Alan Neal, CSci, MSc, FIBMS, quality manager and lead of specialty, hematology, at Pathology Associates Recorded: Apr 19 2016 65 mins
    Learn how Beckman Coulter’s hematology and laboratory automation technologies have helped standardize procedures, deliver consistent turnaround time, reduce manual intervention, and achieve high auto validation rates. Alan Neal will share how his laboratory implemented Beckman Coulter automation and LEAN manufacturing principles.
  • The truth about delivering clinical research in the UK? The truth about delivering clinical research in the UK? Dr Matt Cooper, Business Development and Marketing Director Recorded: Mar 2 2016 34 mins
    •Are you looking to deliver your research within Europe?
    •Do you need multiple, reliable sites and experienced investigators?
    •Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that has all changed with the Department of Health’s investment in the clinical research network infrastructure in the UK.

    Over the last seven years the research landscape in the UK has improved dramatically allowing the UK to make great strides in delivering research for the Life Sciences industry. So whether you are a Pharmaceutical Company, Contract Research Organisation, Biotech, Med Tech or Diagnostic company we can help.

    The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research. This session will be hosted by Dr Matt Cooper, Business Development and Marketing Director, of the National Institute for Health Research Clinical Research Network (NIHR CRN). It will include performance data that will demonstrate why the UK should be your first choice for running clinical research studies.

    You can discover:
    •How much the UK’s market volume of commercial contract research has grown and how we recruited over 34,000 patients to commercial clinical trials in 2014/15
    •What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR CRN)
    •The free feasibility service run by the NIHR CRN
    •How to gain access to our experienced clinical experts
    •How we are keeping clinical research in the public eye
    •How the UK is sharpening its competitive edge by achieving more key first global patients

    The NIHR CRN is exhibiting at the BioPharma Asia Convention 2016, visit stand B22 from 22-24 March to find out more about what we do to support clinical research and how we can help you deliver your studies in the UK.
  • Designing the Next Phase in Genome Editing: Advanced CRISPR Applications Designing the Next Phase in Genome Editing: Advanced CRISPR Applications Jeremy Lehmann- CRISPR Product Specialist, Functional Genomics, MilliporeSigma Recorded: Mar 1 2016 44 mins
    CRISPR Cas9 nucleases have revolutionized the field of genome editing enabling unprecedented efficiency of gene targeting in a vast array of cell types and organisms. Even with such powerful technology at hand, researchers who are new to the field may find genome modification to be challenging and time-consuming. As CRISPR becomes a focus of the molecular biology research community, MilliporeSigma seeks to share the best approaches learned and methods applied in our years of genome editing experience. Today’s presentation will focus on practical applications of CRISPR for pristine genome editing to achieve knockout as well as specific sequence changes to include donor-mediated snps, reporter-tags and conditional knockouts. Special attention will be paid to design considerations for the donor constructs necessary to achieve specific sequence changes. Finally, the frontiers of CRISPR technology, including synthetic crRNA to fast-track genome editing experiments, whole genome screening and targeted gene activation will be explored.
  • Patient centricity 101: How to create content that REALLY communicates Patient centricity 101: How to create content that REALLY communicates Andrew Bromley (SDL); Chris McCourt (SDL); Paul Mitchel (Acurian) Recorded: Feb 23 2016 53 mins
    According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011, delays for launching clinical trials rose by 90%. And with approximately one third of the clinical trial timeline spent in patient recruitment, delays in launching clinical trials will increase costs and drain resources.

    As our industry moves to become fully and demonstrably patient centric, there is much focus on the materials and media which are often the key liaison with the patient populous. As important as what we are saying and where these conversations are taking place may be, it is only part of the conundrum. Developing, maintaining and managing content is a continuous challenge, made all the more taxing not only by strict internal deadlines but the cultural, linguistic and regulatory challenges that go hand in hand with managing global communications.

    Working with our expert partner SDL , we present a live webinar which will deliver insight and guidance on this topic, look in depth at one of the more traditional areas of patient liaison – trial recruitment – and bring you advice from the ‘frontline’ on what works in tackling these content challenges.

    On this latest live webinar, we’ll be discussing:
    •How to develop patient-centric recruitment content that REALLY communicates
    •Best practices of how to handle the linguistic, cultural and regulatory challenges often faced with creating multilingual patient-centric content
    •How simple content management best practices can help you become more patient centric with your content
    •Recent case studies: we’ll be discussing recent successes of global pharmaceutical businesses that have optimised and streamlined recruitment processes with relevant, accurate content development in the right language.
  • Measuring the cost of the right interventions in diabetes Measuring the cost of the right interventions in diabetes John Grumitt, IDF/Diabetes UK, Prof Michael Trenell, Newcastle University, Dr Phil McEwan Sep 8 2016 2:00 pm UTC 75 mins
    Diabetes is one of the most prevalent and most costly conditions worldwide – with a prevalence equating to 8.5% of the global population. Due to the complex nature of diabetes, with numerous co-morbidities and its asymptomatic nature, accurately modelling and therefore discerning which interventions are most effective, in terms of cost and patient impact is an equally complicated process.

    This webinar will explore the patient pathway and how effective modelling – when pharma works together with healthcare stakeholders – can improve outcomes for both patients and the healthcare system as a whole.
  • Getting closer to your customer through video technology Getting closer to your customer through video technology Damian Eade, Tim Williams, Andrew McConaghie Sep 14 2016 2:00 pm UTC 75 mins
    Video content accounted for 64% of all the world’s internet traffic in 2014 and is expected to grow to 80% by 2019. As the way in which we connect and digest information evolves, high quality mobile video capture and advanced digital analysis offers ever more authentic, intimate and rich insights into the customers’ world. This webinar will focus on:
    – How emerging technology can enable us to realise the true value of ‘video data’ in our analysis and beyond
    – How mobile technology can be used to get you closer to your customers and their real world experiences right from the earliest stages in product development
    – How real world video content can engage your key stakeholders and ensure customer insights drive action
  • Quantitative Image Analysis and Emerging Applications on the ImageStream Quantitative Image Analysis and Emerging Applications on the ImageStream Brian Hall, Senior Scientist at Millipore Sigma Sep 21 2016 4:00 pm UTC 75 mins
    The ImageStream is a multispectral imaging flow cytometer that generates high resolution images of cells at a rate of 1000’s of cells per second. This allows for the rapid acquisition of tens of thousands of images per sample. Using the IDEAS image analysis software, the system calculates features based not only on fluorescence intensity but the morphology of that fluorescence as well. With this novel approach the ImageStream is able to seamlessly combine the quantitative power of flow cytometry with the high content information associated with microscopy. The system can collect data on a wide range of applications including nuclear localization during a signal transduction cascade, measuring colocalization of two probes, or quantify features on the phagocytosed particles in macrophages.